A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1287 administered daily to patients with advanced solid tumors.

被引：0
|
作者：
Ben George
Richards, Donald A.
Edenfield, William Jeffory
Warner, Steven L.
Mouritsen, Lars
Bishop, Reyna
Anthony, Stephen Patrick
Bearss, David
Vogelzang, Nicholas J.
Whatcott, Clifford
机构：
[1] Froedtert, Milwaukee, WI USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] US Oncol Res, Tyler, TX USA
[4] Prisma Hlth Upstate Canc Inst, Inst Translat Oncol Res, Greenville, SC USA
[5] Tolero Pharmaceut Inc, Lehi, UT USA
[6] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3611
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 administered daily for 28 days to patients with advanced solid tumors.
    Garrido-Laguna, Ignacio
    Dillon, Patrick Michael
    Anthony, Stephen Patrick
    Janat-Amsbury, Margit
    Ashenbramer, Nissa
    Warner, Steven L.
    Mouritsen, Lars
    Wade, Mark L.
    Whatcott, Clifford
    Bearss, David
    Fu, Siqing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.
    Sarantopoulos, John
    Beg, Muhammad Shaalan
    Fotopoulos, Georgios
    Taverna, Josephine Amalia
    Anthony, Stephen P.
    Weitman, Steven D.
    Warner, Steven L.
    Mouritsen, Lars
    Bearss, David
    Smith, Susan
    Beever, Holly
    Khemka, Vivek
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654, a PIM kinase inhibitor, in patients with advanced solid tumors
    Garrido-Laguna, Ignacio
    Dillon, Patrick M.
    Kabir, Sujan
    Mei, Jian
    Wade, Mark L.
    Yang, Huyuan
    Stapinski, Carl
    Foulks, Jason M.
    Warner, Steven L.
    Whatcott, Clifford
    Lebedinsky, Claudia
    Fu, Siqing
    [J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [4] Phase 1, first-in-human, dose-escalation study of oral TP-1287, a cyclin dependent kinase 9 (CDK9) inhibitor, in patients (pts) with advanced solid tumors (ASTs).
    Vogelzang, Nicholas J.
    George, Ben
    Ashenbramer, Nissa
    Edenfield, William J.
    Richards, Donald
    Gross, Mitchell E.
    Fine, Gil D.
    Martinez, Pablo
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [5] A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
    Rodon, Jordi
    Tawbi, Hussein A.
    Thomas, Anne L.
    Stoller, Ronald G.
    Turtschi, Christian P.
    Baselga, Jose
    Sarantopoulos, John
    Mahalingam, Devalingam
    Shou, Yaping
    Moles, Melissa A.
    Yang, Lin
    Granvil, Camille
    Hurh, Eunju
    Rose, Kristine L.
    Amakye, Dereck D.
    Dummer, Reinhard
    Mita, Alain C.
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1900 - 1909
  • [6] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
    Park, John J.
    Gao, Bo
    Beecroft, Claire
    Wilkinson, Kate Jessica
    Parsonson, Andrew
    Zhang, Karl
    Yan, Xiangyun
    Wang, Ni
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
    Beecroft, Claire
    Gao, Bo
    Park, John
    Wilkinson, Kate
    Zhang, Karl
    Yan, Xiangyun
    Lv, Yuan
    [J]. CANCER RESEARCH, 2024, 84 (07)
  • [8] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
    Michael S. Gordon
    David S. Mendelson
    Mitchell Gross
    Martina Uttenreuther-Fischer
    Mahmoud Ould-Kaci
    Yihua Zhao
    Peter Stopfer
    David B. Agus
    [J]. Investigational New Drugs, 2013, 31 : 409 - 416
  • [9] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
    Gordon, Michael S.
    Mendelson, David S.
    Gross, Mitchell
    Uttenreuther-Fischer, Martina
    Ould-Kaci, Mahmoud
    Zhao, Yihua
    Stopfer, Peter
    Agus, David B.
    [J]. INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 409 - 416
  • [10] A phase I dose escalation and pharmacodynamic study of weekly administered AlbuleukinTM in patients with advanced solid tumors.
    Agarwala, SS
    Bukowski, RM
    Kirkwood, J
    Weiss, P
    Olencki, T
    Grzegorewski, KJ
    Melder, R
    Fox, RA
    Herpst, JM
    Gallant, G
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6230S - 6231S
12345